Abstract
Objective: To analyze the factors associated with survival and to describe the specific causes of death in a large cohort of individuals with Acquired Immune Deficiency Syndrome (AIDS) in the Highly Active Antiretroviral Therapy (HAART) era. Methods: Subjects over 13 years old recorded in the AIDS registry of Barcelona and diagnosed between 1997-2005 were included. Survival analysis was performed. Causes of death were classified as being HIV-related or non- HIV-related. Results: A total of 1,759 cases were analyzed, 640 (36.3%) of them died during the follow-up. The cumulative probability of survival at five years was of 64% (95% C.I. 62%-67%). The cause of death was non-HIV-related in 28.9% of the cases, among which the most frequent were cancers (20.8%) and liver diseases (18.8%). Conclusion: An increase in the proportion of non-HIV-related deaths has been observed compared to that in the pre-HAART era. The case management of HIV-infected people must be re-directed to influence the risk factors associated with these increasing causes of death.
Keywords: AIDS, survival, cause of death, risk factors, epidemiology
Current HIV Research
Title: Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era
Volume: 6 Issue: 1
Author(s): Patricia G. de Olalla, Ana M. Novoa, Roser Clos, Angels Orcau, Maica Rodriguez-Sanz and Joan A. Cayla
Affiliation:
Keywords: AIDS, survival, cause of death, risk factors, epidemiology
Abstract: Objective: To analyze the factors associated with survival and to describe the specific causes of death in a large cohort of individuals with Acquired Immune Deficiency Syndrome (AIDS) in the Highly Active Antiretroviral Therapy (HAART) era. Methods: Subjects over 13 years old recorded in the AIDS registry of Barcelona and diagnosed between 1997-2005 were included. Survival analysis was performed. Causes of death were classified as being HIV-related or non- HIV-related. Results: A total of 1,759 cases were analyzed, 640 (36.3%) of them died during the follow-up. The cumulative probability of survival at five years was of 64% (95% C.I. 62%-67%). The cause of death was non-HIV-related in 28.9% of the cases, among which the most frequent were cancers (20.8%) and liver diseases (18.8%). Conclusion: An increase in the proportion of non-HIV-related deaths has been observed compared to that in the pre-HAART era. The case management of HIV-infected people must be re-directed to influence the risk factors associated with these increasing causes of death.
Export Options
About this article
Cite this article as:
de Olalla G. Patricia, Novoa M. Ana, Clos Roser, Orcau Angels, Rodriguez-Sanz Maica and Cayla A. Joan, Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era, Current HIV Research 2008; 6 (1) . https://dx.doi.org/10.2174/157016208783572017
DOI https://dx.doi.org/10.2174/157016208783572017 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies
Anti-Cancer Agents in Medicinal Chemistry DNA Copy Number Profiles Correlate with Outcome in Colorectal Cancer Patients Treated with Fluoropyrimidine/Antifolate-based Regimens
Current Drug Metabolism Is Src a Viable Target for Treating Solid Tumours?
Current Cancer Drug Targets Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations
Current Medicinal Chemistry Other Potential Therapeutic Targets in Thyroid Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Molecular Targeting of Aberrant Transcription Factors in Leukemia: Strategies for RUNX1/ETO
Current Drug Targets What Western Pharmacists Need to Know About Traditional Chinese Medicine; A Canadian Perspective
Current Traditional Medicine Therapeutic Potential of Inhibiting Brutons Tyrosine Kinase, (BTK)
Current Pharmaceutical Design Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry Impact of Immunogenetic Polymorphisms in Bone Marrow Failure Syndromes
Mini-Reviews in Medicinal Chemistry Alternatives to Conventional Vaccines - Mediators of Innate Immunity
Current Drug Targets Leukaemia Infection Diagnosis and Intestinal Flora Disorder
Current Molecular Medicine Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Clinical Presentation, Outcome and Risk Factors of Late-Onset Non- Infectious Pulmonary Complications After Allogeneic Stem Cell Transplantation
Current Stem Cell Research & Therapy Cellular and Humoral Responses following Minimally Invasive Surgery: Role of Reactive Oxygen Species
Current Metabolomics Oral and Dental Considerations in the Management of Leukemic Children
Applied Clinical Research, Clinical Trials and Regulatory Affairs Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design Understanding XPO1 Target Networks Using Systems Biology and Mathematical Modeling
Current Pharmaceutical Design Mouse Induced Glioma-Initiating Cell Models and Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry